Search research articles
Contact Us
Filters
Showing results (31-40 of 53) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2007
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy
Henri Roché, Louise Yelle, Francesco Cognetti, et al.
Cancer Research
|
October 16, 2003
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status
Matthew J Ellis, Andrew Coop, Baljit Singh, et al.
The New England Journal of Medicine
|
August 21, 2009
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
, Henning Mouridsen, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2004
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer
Véronique Diéras, Pierre Fumoleau, Gilles Romieu, et al.
Breast Cancer Research and Treatment
|
July 16, 2010
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
Kathleen I Pritchard, Janusz Rolski, Zsuzsanna Papai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results
Joyce O'Shaughnessy, David Miles, Svetislava Vukelja, et al.
The Lancet. Oncology
|
May 3, 2005
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial
Andrew Bottomley, Patrick Therasse, Martine Piccart, et al.
Cancer
|
July 23, 2003
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials
John F R Robertson, C Kent Osborne, Anthony Howell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2008
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT
Stephen Chia, William Gradishar, Louis Mauriac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2007
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
Henning Mouridsen, Aparna Keshaviah, Alan S Coates, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 53) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2007
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy
Henri Roché, Louise Yelle, Francesco Cognetti, et al.
Cancer Research
|
October 16, 2003
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status
Matthew J Ellis, Andrew Coop, Baljit Singh, et al.
The New England Journal of Medicine
|
August 21, 2009
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
, Henning Mouridsen, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2004
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer
Véronique Diéras, Pierre Fumoleau, Gilles Romieu, et al.
Breast Cancer Research and Treatment
|
July 16, 2010
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
Kathleen I Pritchard, Janusz Rolski, Zsuzsanna Papai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results
Joyce O'Shaughnessy, David Miles, Svetislava Vukelja, et al.
The Lancet. Oncology
|
May 3, 2005
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial
Andrew Bottomley, Patrick Therasse, Martine Piccart, et al.
Cancer
|
July 23, 2003
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials
John F R Robertson, C Kent Osborne, Anthony Howell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2008
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT
Stephen Chia, William Gradishar, Louis Mauriac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2007
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
Henning Mouridsen, Aparna Keshaviah, Alan S Coates, et al.
Page
of 6